GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Shiller PE Ratio

Arena Pharmaceuticals (Arena Pharmaceuticals) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arena Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Shiller PE Ratio Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Shiller PE Ratio falls into.



Arena Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arena Pharmaceuticals's E10 for the quarter that ended in Dec. 2021 is calculated as:

For example, Arena Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-2.54/117.6295*117.6295
=-2.540

Current CPI (Dec. 2021) = 117.6295.

Arena Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201203 -1.800 96.783 -2.188
201206 -1.200 96.819 -1.458
201209 -0.700 97.633 -0.843
201212 -1.000 96.871 -1.214
201303 -0.900 98.209 -1.078
201306 1.800 98.518 2.149
201309 -0.800 98.790 -0.953
201312 -1.100 98.326 -1.316
201403 -1.200 99.695 -1.416
201406 0.300 100.560 0.351
201409 -0.500 100.428 -0.586
201412 -1.500 99.070 -1.781
201503 -1.000 99.621 -1.181
201506 -1.100 100.684 -1.285
201509 -1.100 100.392 -1.289
201512 -1.300 99.792 -1.532
201603 -0.900 100.470 -1.054
201606 -1.120 101.688 -1.296
201609 -0.510 101.861 -0.589
201612 1.600 101.863 1.848
201703 -0.900 102.862 -1.029
201706 -0.770 103.349 -0.876
201709 -0.860 104.136 -0.971
201712 -0.350 104.011 -0.396
201803 -0.800 105.290 -0.894
201806 -0.650 106.317 -0.719
201809 -0.700 106.507 -0.773
201812 1.350 105.998 1.498
201903 12.100 107.251 13.271
201906 -1.240 108.070 -1.350
201909 -1.460 108.329 -1.585
201912 -1.760 108.420 -1.909
202003 -2.000 108.902 -2.160
202006 -1.610 108.767 -1.741
202009 -1.690 109.815 -1.810
202012 -2.100 109.897 -2.248
202103 -1.980 111.754 -2.084
202106 -2.400 114.631 -2.463
202109 -3.210 115.734 -3.263
202112 -2.540 117.630 -2.540

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arena Pharmaceuticals  (NAS:ARNA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arena Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Executives
Amit Munshi director, officer: President and CEO C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki officer: EVP, Chief Commercial Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz officer: Executive VP and CBO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell officer: EVP, Head of R&D, and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer officer: EVP & Chief Financial Officer 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt officer: EVP, General Counsel & Sec C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind officer: Executive VP and CFO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121